Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adrenal Suppression Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

NCT02932891
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DSXS topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation

NCT01421797
View directory record Official record
Conditions
Hyperandrogenemia, Polycystic Ovary Syndrome, Obesity
Interventions
Dexamethasone, Cortrosyn
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jun 25, 2026, 9:41 PM EDT
Completed No phase listed Observational

Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy

NCT01209507
View directory record Official record
Conditions
Adrenal Suppression
Interventions
Chemotherapy
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris

NCT02720627
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
9 Years to 11 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Fort Smith, Arkansas • San Diego, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate

NCT00575029
View directory record Official record
Conditions
Adrenal Insufficiency
Interventions
megestrol acetate
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
65 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2011 · Synced Jun 25, 2026, 9:41 PM EDT
Withdrawn Early Phase 1 Interventional

Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction

NCT01422733
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone, dexamethasone, Cosyntropin, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 16 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product

NCT02933502
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
DSXS topical product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS

NCT02933528
View directory record Official record
Conditions
Psoriasis
Interventions
DSXS Topical product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Active and Passive Music Therapy Interventions

NCT03362944
View directory record Official record
Conditions
Autonomic Nervous System Imbalance, Hypothalamic Pituitary Adrenal Axis Suppression
Interventions
Active Music Therapy, Passive Music Therapy
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 34 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris

NCT01831960
View directory record Official record
Conditions
Acne Vulgaris
Interventions
cortexolone 17α-propionate
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Boise, Idaho • Carmel, Indiana • Clinton Township, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 4 Interventional Results available

Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis

NCT03992261
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Topical Foam
Drug
Lead sponsor
Mayne Pharma International Pty Ltd
Industry
Eligibility
12 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Hialeah, Florida • Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis

NCT02601469
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study

NCT03709381
View directory record Official record
Conditions
Adrenal Insufficiency, Osteopenia, Osteoporosis, Steroid Suppression of ACTH Secretion
Interventions
Low Dose Cosyntropin (ACTH) stimulation test, High Dose Cosyntropin (ACTH) stimulation test
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
9 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Jun 25, 2026, 9:41 PM EDT
Terminated Phase 3 Interventional Results available

DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis

NCT02527421
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DFD01 Spray
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
12 Years to 16 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Encino, California • Irvine, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 4 Interventional Results available

Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis

NCT02340169
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Topicort® (desoximetasone) Topical Spray, 0.25%
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression

NCT02932878
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DSXS topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02070965
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
DFD01 Spray, Comp01 Lotion
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Encinitas, California • Encino, California • Santa Rosa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Desoximetasone Spray 0.25%, Hypothalamic Pituitary Adrenal (HPA) Axis Study

NCT01043393
View directory record Official record
Conditions
Psoriasis
Interventions
Desoximetasone 0.25% spray
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Hot Springs, Arkansas • Albuquerque, New Mexico • Simpsonville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis

NCT02131324
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06 Cream, Clobetasol Propionate Cream 0.05%
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Glendale, Arizona • Mesa, Arizona • Encino, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%

NCT03212963
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Topical Lotion
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 16 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Fountain Valley, California • Hialeah, Florida • Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Jun 25, 2026, 9:41 PM EDT
Terminated Phase 2 Interventional Results available

Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

NCT03179605
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06
Drug
Lead sponsor
Primus Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
9
States / cities
Madera, California • Santa Ana, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jun 25, 2026, 9:41 PM EDT
Withdrawn Early Phase 1 Interventional

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422707
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

NCT01698333
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
122-0551
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Anaheim, California • San Diego, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jun 25, 2026, 9:41 PM EDT
Completed Phase 2 Interventional

Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

NCT01232543
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Product 0405
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2012 · Synced Jun 25, 2026, 9:41 PM EDT